Neurogenomics Global Market Report 2025

Neurogenomics is the study of how the genome affects the development and function of the nervous system, integrating neuroscience and genomics to better understand brain-related diseases, behavior, and cognition. Through the analysis of gene expression and genetic variations, researchers aim to uncover the underlying mechanisms of neurological disorders, advancing personalized medicine approaches in neurology.

The primary offerings in neurogenomics include next-generation sequencing (NGS), polymerase chain reaction (PCR), microarrays, and related software and services. Next-generation sequencing is a high-throughput DNA sequencing technology that enables the rapid and parallel analysis of millions of DNA fragments to determine their precise sequence. These technologies support a wide array of applications, including variant discovery, research studies, target identification, transcription factor binding analysis, functional genomics, and clinical diagnostics. Key end users include pharmaceutical and biotechnology companies, academic and research institutions, and hospitals and diagnostic laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The neurogenomics market research report is one of a series of new reports from The Business Research Company that provides neurogenomics market statistics, including neurogenomics global market size, regional shares, competitors with neurogenomics market share, detailed neurogenomics market segments, market trends and opportunities, and any further data you may need to thrive in the neurogenomics industry. The neurogenomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neurogenomics market size has grown rapidly in recent years. It will grow from $1.31 billion in 2024 to $1.50 billion in 2025 at a compound annual growth rate (CAGR) of 15.0%. Growth during the historic period can be attributed to the rising demand for genetic testing in neurological disorders, increased research on the connections between the brain, behavior, and genome, the growing prevalence of neurodegenerative diseases, increased funding for neuroscience research, and the expansion of biobanks and genomic databases.

The neurogenomics market size is expected to see rapid growth in the next few years. It will grow to $2.60 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. Growth in the forecast period can be attributed to the rising interest in personalized treatments for mental health, increased use of direct-to-consumer neurogenetic testing, growing adoption of multi-omics approaches, expansion of precision neurology initiatives, and greater use of targeted therapies. Key trends expected during this period include the development of artificial intelligence-powered genomic analytics, advancements in non-invasive diagnostic platforms, integration of multi-omics technologies, incorporation of genomics into precision neurology, and innovations in modeling neurodegenerative diseases.

The rising prevalence of neurological disorders is expected to drive the growth of the neurogenomics market in the coming years. Neurological disorders are medical conditions that impact the brain, spinal cord, or nerves and can cause symptoms such as muscle weakness, seizures, chronic pain, or cognitive impairments. This increase in prevalence is largely attributed to lifestyle-related factors, including poor dietary habits, insufficient physical activity, chronic stress, and greater exposure to environmental toxins. Neurogenomics plays a crucial role in addressing these disorders by offering insights into the genetic underpinnings of brain function and dysfunction, thereby improving diagnosis, identifying root causes, and enabling targeted treatments. For example, in March 2023, the Alzheimer's Association reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia. This figure is projected to increase to 13.8 million by 2060. Thus, the growing incidence of neurological disorders is contributing to the expansion of the neurogenomics market.

Leading companies in the neurogenomics market are focusing on developing cutting-edge technologies such as whole genome sequencing platforms to improve the diagnosis and understanding of rare and complex neurological conditions. Whole genome sequencing platforms analyze the complete DNA sequence of an individual's genome and are instrumental in identifying genetic factors linked to neurological disorders. For instance, in April 2023, Centogene N.V., a Germany-based diagnostics and research company specializing in rare diseases, introduced CentoGenome, the world's most comprehensive whole-genome sequencing (WGS) solution for diagnosing rare and neurodegenerative conditions. This platform incorporates PCR-free technology for high-quality, unbiased sequencing, particularly across difficult-to-sequence genetic regions. It improves variant detection through a sophisticated bioinformatics pipeline and expert analysis, capturing nearly all disease-causing variants in a single test. The service also includes integrated, lifelong diagnostic support, with free variant reclassification and confirmatory testing as new genetic insights emerge.

In February 2025, Tempus AI Inc., a US-based health technology company, acquired Ambry Genetics for $600 million. This acquisition was intended to enhance Tempus AI's precision medicine platform by incorporating Ambry Genetics' specialized capabilities in hereditary and clinical genetic testing. The integration broadens Tempus AI's reach across various therapeutic areas, including oncology, cardiology, rare diseases, and neurological conditions. Ambry Genetics Corporation, a US-based genetic testing company, provides neurogenomics services through a wide array of genetic testing options for neurological and neurodevelopmental disorders.

Major players in the neurogenomics market are F. Hoffmann-La Roche Limited, Thermo Fisher Scientific Incorporated, Danaher Corporation, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Myriad Genetics Inc., GeneDx LLC, Fulgent Genetics Inc., Oxford Nanopore Technologies Plc., Vigil Neuroscience Inc., PacBio, MedGenome Labs Ltd., MGI Tech Co. Ltd., Centogene N.V., Variantyx Inc., and Neurogene.

North America was the largest region in the neurogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neurogenomics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurogenomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurogenomics market consists of revenues earned by entities by providing services such as genomic sequencing services, bioinformatics and data analysis, research and clinical trial support, customized gene panel development, and pharmacogenomics services. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurogenomics market also includes sales of genomic sequencing kits, microarray chips, bioinformatics software, neurogenomic biomarkers, and single-cell genomics kits. Values in this market are 'factory gate' values that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurogenomics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurogenomics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurogenomics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neurogenomics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Offering: Next-Generation Sequencing; Polymerase Chain Reaction; Microarray; Software And Services
• 2) By Application: Variant Discovery; Research Applications; Target Identification; Transcription Factor Binding Analysis; Functional Studies; Clinical Applications
• 3) By End User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Hospitals And Diagnostic Laboratories
• Subsegments:
• 1) By Next-Generation Sequencing: Whole Genome Sequencing; Whole Exome Sequencing; Targeted Sequencing; Ribonucleic Acid Sequencing
• 2) By Polymerase Chain Reaction: Real-Time Polymerase Chain Reaction; Reverse Transcription Polymerase Chain Reaction; Digital Polymerase Chain Reaction
• 3) By Microarray: Deoxyribonucleic Acid Microarray; Ribonucleic Acid Microarray; Protein Microarray
• 4) By Software And Services: Data Analysis And Interpretation Software; Genomic Data Management Tools; Custom Services; Cloud-Based Platforms And Reporting Tools
• Companies Mentioned: F. Hoffmann-La Roche Limited; Thermo Fisher Scientific Incorporated; Danaher Corporation; Quest Diagnostics Incorporated; Eurofins Scientific SE; Agilent Technologies Inc.; Illumina Inc.; Revvity Inc.; QIAGEN N.V.; Myriad Genetics Inc.; GeneDx LLC; Fulgent Genetics Inc.; Oxford Nanopore Technologies Plc; Vigil Neuroscience Inc.; PacBio; MedGenome Labs Ltd.; MGI Tech Co. Ltd.; Centogene N.V.; Variantyx Inc.; Neurogene.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.